Collegium Pharma (COLL): Management Changes A Positive - Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Collegium Pharma (COLL) Secures Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
June 1, 2017 7:13 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective June 1, 2017, Xtampza ER is the exclusive oxycodone extended-release product for this... More
